STOCK TITAN

[8-K] American Eagle Outfitters Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

On 1 July 2025, venture fund 5AM Opportunities I, L.P. filed a Form 144 indicating its intent to sell up to 6,422 common shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA) through TD Securities (USA) LLC. The proposed transaction is valued at roughly USD 45,737 and represents only 0.02 % of Entrada’s 37.95 million shares outstanding.

The filing also discloses that the same fund recently sold 19,265 shares on 27 Jun 2025 for USD 133,121 and 6,422 shares on 30 Jun 2025 for USD 43,751, bringing total sales in the past three months to 25,687 shares (≈ 0.07 % of the float) for gross proceeds of approximately USD 176,872.

The shares were originally acquired on 29 Mar 2021 via a cash-financed venture investment. No operational, earnings, or strategic updates are provided in this notice. Form 144 merely gives advance notice of potential affiliate sales; execution is not assured. Given the small size relative to the public float, the filing is unlikely to materially affect liquidity or valuation but does indicate continued position trimming by an early investor.

Il 1° luglio 2025, il fondo di venture capital 5AM Opportunities I, L.P. ha presentato un modulo Form 144 indicando l'intenzione di vendere fino a 6.422 azioni ordinarie di Entrada Therapeutics, Inc. (NASDAQ: TRDA) tramite TD Securities (USA) LLC. La transazione proposta ha un valore approssimativo di USD 45.737 e rappresenta solo lo 0,02 % delle 37,95 milioni di azioni in circolazione di Entrada.

La comunicazione rivela inoltre che lo stesso fondo ha recentemente venduto 19.265 azioni il 27 giugno 2025 per USD 133.121 e 6.422 azioni il 30 giugno 2025 per USD 43.751, portando le vendite totali negli ultimi tre mesi a 25.687 azioni (circa lo 0,07 % del flottante) per un ricavo lordo di circa USD 176.872.

Le azioni erano state originariamente acquistate il 29 marzo 2021 tramite un investimento di venture capital finanziato in contanti. Nessun aggiornamento operativo, sui guadagni o strategico è fornito in questo avviso. Il modulo Form 144 serve solo come preavviso di potenziali vendite da parte di affiliati; l'esecuzione non è garantita. Data la piccola dimensione rispetto al flottante pubblico, la comunicazione difficilmente influirà in modo significativo sulla liquidità o sulla valutazione, ma indica un continuo ridimensionamento della posizione da parte di un investitore iniziale.

El 1 de julio de 2025, el fondo de capital de riesgo 5AM Opportunities I, L.P. presentó un Formulario 144 indicando su intención de vender hasta 6.422 acciones ordinarias de Entrada Therapeutics, Inc. (NASDAQ: TRDA) a través de TD Securities (USA) LLC. La transacción propuesta tiene un valor aproximado de USD 45.737 y representa solo el 0,02 % de las 37,95 millones de acciones en circulación de Entrada.

La presentación también revela que el mismo fondo vendió recientemente 19.265 acciones el 27 de junio de 2025 por USD 133.121 y 6.422 acciones el 30 de junio de 2025 por USD 43.751, sumando ventas totales en los últimos tres meses de 25.687 acciones (aproximadamente el 0,07 % del flotante) por ingresos brutos de aproximadamente USD 176.872.

Las acciones fueron adquiridas originalmente el 29 de marzo de 2021 mediante una inversión de capital de riesgo financiada en efectivo. No se proporcionan actualizaciones operativas, de ganancias o estratégicas en este aviso. El Formulario 144 solo da aviso previo de posibles ventas por parte de afiliados; la ejecución no está garantizada. Dado el pequeño tamaño en relación con el flotante público, es poco probable que la presentación afecte materialmente la liquidez o valoración, pero indica un continuo recorte de posición por parte de un inversor temprano.

2025년 7월 1일, 벤처 펀드 5AM Opportunities I, L.P.가 TD Securities (USA) LLC를 통해 Entrada Therapeutics, Inc. (NASDAQ: TRDA)6,422주 보통주를 매도할 의사를 나타내는 Form 144를 제출했습니다. 제안된 거래 가치는 약 미국 달러 45,737달러이며 Entrada의 3,795만 주 유통 주식 중 0.02%에 해당합니다.

해당 제출서류는 동일 펀드가 최근 2025년 6월 27일에 19,265주를 133,121달러에, 2025년 6월 30일에 6,422주를 43,751달러에 매도했음을 공개하며, 지난 3개월간 총 매도 주식은 25,687주(약 0.07% 유통 주식)로 총 매출은 약 176,872달러임을 나타냅니다.

이 주식들은 2021년 3월 29일 현금으로 조달된 벤처 투자로 처음 취득되었습니다. 본 공지에는 운영, 수익 또는 전략적 업데이트가 포함되어 있지 않습니다. Form 144는 잠재적 계열사 매도에 대한 사전 통지일 뿐이며, 실제 매도 실행을 보장하지 않습니다. 공개 유통 주식 대비 규모가 작기 때문에, 이번 제출은 유동성이나 평가에 큰 영향을 미치지 않을 것으로 보이나 초기 투자자의 지속적인 보유 주식 축소를 시사합니다.

Le 1er juillet 2025, le fonds de capital-risque 5AM Opportunities I, L.P. a déposé un formulaire 144 indiquant son intention de vendre jusqu'à 6 422 actions ordinaires de Entrada Therapeutics, Inc. (NASDAQ : TRDA) par l'intermédiaire de TD Securities (USA) LLC. La transaction proposée est évaluée à environ 45 737 USD et ne représente que 0,02 % des 37,95 millions d'actions en circulation d'Entrada.

Le dépôt révèle également que le même fonds a récemment vendu 19 265 actions le 27 juin 2025 pour 133 121 USD et 6 422 actions le 30 juin 2025 pour 43 751 USD, portant le total des ventes au cours des trois derniers mois à 25 687 actions (environ 0,07 % du flottant) pour un produit brut d'environ 176 872 USD.

Les actions ont été initialement acquises le 29 mars 2021 via un investissement en capital-risque financé en numéraire. Aucun mise à jour opérationnelle, de résultats ou stratégique n'est fournie dans cet avis. Le formulaire 144 sert uniquement d'avis préalable de ventes potentielles par des affiliés ; l'exécution n'est pas assurée. Étant donné la taille réduite par rapport au flottant public, cette déclaration est peu susceptible d'affecter significativement la liquidité ou la valorisation, mais indique un ajustement continu de la position par un investisseur précoce.

Am 1. Juli 2025 reichte der Venture-Fonds 5AM Opportunities I, L.P. ein Formular 144 ein, in dem er seine Absicht bekundet, bis zu 6.422 Stammaktien von Entrada Therapeutics, Inc. (NASDAQ: TRDA) über TD Securities (USA) LLC zu verkaufen. Der vorgeschlagene Handel hat einen Wert von etwa 45.737 USD und entspricht nur 0,02 % der 37,95 Millionen ausstehenden Aktien von Entrada.

Die Meldung offenbart außerdem, dass derselbe Fonds kürzlich am 27. Juni 2025 19.265 Aktien für 133.121 USD und am 30. Juni 2025 6.422 Aktien für 43.751 USD verkauft hat, womit die Gesamtverkäufe in den letzten drei Monaten 25.687 Aktien (≈ 0,07 % des Streubesitzes) für Bruttoerlöse von etwa 176.872 USD betragen.

Die Aktien wurden ursprünglich am 29. März 2021 durch eine barfinanzierte Venture-Investition erworben. Es werden keine operativen, Gewinn- oder strategischen Updates in dieser Mitteilung bereitgestellt. Das Formular 144 dient lediglich als Vorabmitteilung potenzieller Verkäufe von verbundenen Parteien; eine Ausführung ist nicht garantiert. Aufgrund der geringen Größe im Vergleich zum öffentlichen Streubesitz wird die Meldung voraussichtlich keine wesentlichen Auswirkungen auf Liquidität oder Bewertung haben, deutet jedoch auf eine fortgesetzte Positionsreduzierung durch einen frühen Investor hin.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Minor insider sale—6.4k shares (0.02 %) planned; unlikely to move TRDA stock materially.

The filing signals a routine disposal of a modest stake by 5AM Opportunities I, L.P., following two similarly sized trades earlier in the week. Aggregate sales of 25.7k shares over three months are immaterial to Entrada’s 37.9 million-share float and generate less than USD 0.2 million in proceeds—negligible versus the company’s market cap. No adverse operational information accompanies the notice, so the market impact should be neutral barring sentiment-driven reactions to continued venture-fund selling.

TL;DR: Routine affiliate filing; no governance red flags, impact minimal.

Form 144 compliance shows the seller is observing SEC disclosure rules. The representation statement affirms no undisclosed adverse information, and there is no indication of a 10b5-1 plan. The modest share count and voluntary disclosure timing suggest orderly liquidation rather than urgency or insider concern. From a governance perspective, this is a standard event with no material implications.

Il 1° luglio 2025, il fondo di venture capital 5AM Opportunities I, L.P. ha presentato un modulo Form 144 indicando l'intenzione di vendere fino a 6.422 azioni ordinarie di Entrada Therapeutics, Inc. (NASDAQ: TRDA) tramite TD Securities (USA) LLC. La transazione proposta ha un valore approssimativo di USD 45.737 e rappresenta solo lo 0,02 % delle 37,95 milioni di azioni in circolazione di Entrada.

La comunicazione rivela inoltre che lo stesso fondo ha recentemente venduto 19.265 azioni il 27 giugno 2025 per USD 133.121 e 6.422 azioni il 30 giugno 2025 per USD 43.751, portando le vendite totali negli ultimi tre mesi a 25.687 azioni (circa lo 0,07 % del flottante) per un ricavo lordo di circa USD 176.872.

Le azioni erano state originariamente acquistate il 29 marzo 2021 tramite un investimento di venture capital finanziato in contanti. Nessun aggiornamento operativo, sui guadagni o strategico è fornito in questo avviso. Il modulo Form 144 serve solo come preavviso di potenziali vendite da parte di affiliati; l'esecuzione non è garantita. Data la piccola dimensione rispetto al flottante pubblico, la comunicazione difficilmente influirà in modo significativo sulla liquidità o sulla valutazione, ma indica un continuo ridimensionamento della posizione da parte di un investitore iniziale.

El 1 de julio de 2025, el fondo de capital de riesgo 5AM Opportunities I, L.P. presentó un Formulario 144 indicando su intención de vender hasta 6.422 acciones ordinarias de Entrada Therapeutics, Inc. (NASDAQ: TRDA) a través de TD Securities (USA) LLC. La transacción propuesta tiene un valor aproximado de USD 45.737 y representa solo el 0,02 % de las 37,95 millones de acciones en circulación de Entrada.

La presentación también revela que el mismo fondo vendió recientemente 19.265 acciones el 27 de junio de 2025 por USD 133.121 y 6.422 acciones el 30 de junio de 2025 por USD 43.751, sumando ventas totales en los últimos tres meses de 25.687 acciones (aproximadamente el 0,07 % del flotante) por ingresos brutos de aproximadamente USD 176.872.

Las acciones fueron adquiridas originalmente el 29 de marzo de 2021 mediante una inversión de capital de riesgo financiada en efectivo. No se proporcionan actualizaciones operativas, de ganancias o estratégicas en este aviso. El Formulario 144 solo da aviso previo de posibles ventas por parte de afiliados; la ejecución no está garantizada. Dado el pequeño tamaño en relación con el flotante público, es poco probable que la presentación afecte materialmente la liquidez o valoración, pero indica un continuo recorte de posición por parte de un inversor temprano.

2025년 7월 1일, 벤처 펀드 5AM Opportunities I, L.P.가 TD Securities (USA) LLC를 통해 Entrada Therapeutics, Inc. (NASDAQ: TRDA)6,422주 보통주를 매도할 의사를 나타내는 Form 144를 제출했습니다. 제안된 거래 가치는 약 미국 달러 45,737달러이며 Entrada의 3,795만 주 유통 주식 중 0.02%에 해당합니다.

해당 제출서류는 동일 펀드가 최근 2025년 6월 27일에 19,265주를 133,121달러에, 2025년 6월 30일에 6,422주를 43,751달러에 매도했음을 공개하며, 지난 3개월간 총 매도 주식은 25,687주(약 0.07% 유통 주식)로 총 매출은 약 176,872달러임을 나타냅니다.

이 주식들은 2021년 3월 29일 현금으로 조달된 벤처 투자로 처음 취득되었습니다. 본 공지에는 운영, 수익 또는 전략적 업데이트가 포함되어 있지 않습니다. Form 144는 잠재적 계열사 매도에 대한 사전 통지일 뿐이며, 실제 매도 실행을 보장하지 않습니다. 공개 유통 주식 대비 규모가 작기 때문에, 이번 제출은 유동성이나 평가에 큰 영향을 미치지 않을 것으로 보이나 초기 투자자의 지속적인 보유 주식 축소를 시사합니다.

Le 1er juillet 2025, le fonds de capital-risque 5AM Opportunities I, L.P. a déposé un formulaire 144 indiquant son intention de vendre jusqu'à 6 422 actions ordinaires de Entrada Therapeutics, Inc. (NASDAQ : TRDA) par l'intermédiaire de TD Securities (USA) LLC. La transaction proposée est évaluée à environ 45 737 USD et ne représente que 0,02 % des 37,95 millions d'actions en circulation d'Entrada.

Le dépôt révèle également que le même fonds a récemment vendu 19 265 actions le 27 juin 2025 pour 133 121 USD et 6 422 actions le 30 juin 2025 pour 43 751 USD, portant le total des ventes au cours des trois derniers mois à 25 687 actions (environ 0,07 % du flottant) pour un produit brut d'environ 176 872 USD.

Les actions ont été initialement acquises le 29 mars 2021 via un investissement en capital-risque financé en numéraire. Aucun mise à jour opérationnelle, de résultats ou stratégique n'est fournie dans cet avis. Le formulaire 144 sert uniquement d'avis préalable de ventes potentielles par des affiliés ; l'exécution n'est pas assurée. Étant donné la taille réduite par rapport au flottant public, cette déclaration est peu susceptible d'affecter significativement la liquidité ou la valorisation, mais indique un ajustement continu de la position par un investisseur précoce.

Am 1. Juli 2025 reichte der Venture-Fonds 5AM Opportunities I, L.P. ein Formular 144 ein, in dem er seine Absicht bekundet, bis zu 6.422 Stammaktien von Entrada Therapeutics, Inc. (NASDAQ: TRDA) über TD Securities (USA) LLC zu verkaufen. Der vorgeschlagene Handel hat einen Wert von etwa 45.737 USD und entspricht nur 0,02 % der 37,95 Millionen ausstehenden Aktien von Entrada.

Die Meldung offenbart außerdem, dass derselbe Fonds kürzlich am 27. Juni 2025 19.265 Aktien für 133.121 USD und am 30. Juni 2025 6.422 Aktien für 43.751 USD verkauft hat, womit die Gesamtverkäufe in den letzten drei Monaten 25.687 Aktien (≈ 0,07 % des Streubesitzes) für Bruttoerlöse von etwa 176.872 USD betragen.

Die Aktien wurden ursprünglich am 29. März 2021 durch eine barfinanzierte Venture-Investition erworben. Es werden keine operativen, Gewinn- oder strategischen Updates in dieser Mitteilung bereitgestellt. Das Formular 144 dient lediglich als Vorabmitteilung potenzieller Verkäufe von verbundenen Parteien; eine Ausführung ist nicht garantiert. Aufgrund der geringen Größe im Vergleich zum öffentlichen Streubesitz wird die Meldung voraussichtlich keine wesentlichen Auswirkungen auf Liquidität oder Bewertung haben, deutet jedoch auf eine fortgesetzte Positionsreduzierung durch einen frühen Investor hin.

AMERICAN EAGLE OUTFITTERS INC false 0000919012 0000919012 2025-06-25 2025-06-25
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 25, 2025

 

 

AMERICAN EAGLE OUTFITTERS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   1-33338   13-2721761
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

77 Hot Metal Street  
Pittsburgh, Pennsylvania   15203-2329
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (412) 432-3300

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common stock, $0.01 par value   AEO   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


ITEM 5.07. Submission of Matters to a Vote of Security Holders.

On June 25, 2025, American Eagle Outfitters, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) by means of remote communication. As of May 1, 2025, the record date for the Annual Meeting, there were a total of 173,264,684 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 160,279,159 shares of Common Stock were represented in person by virtual participation or by proxy and, therefore, a quorum was present.

The stockholders of the Company voted on the following proposals:

1. To elect two Class III directors to serve until the Company’s 2028 Annual Meeting of Stockholders (“Proposal 1”);

2. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 31, 2026 (“Proposal 2”); and

3. To approve, on an advisory basis, the fiscal 2024 compensation of our named executive officers (“Proposal 3”).

Proposal 1: Votes regarding the election of two Class III directors were as follows:

 

Name

       For           Against          Abstain        Broker Non-Votes 

Deborah A. Henretta

   133,254,208    16,018,391    109,568    10,896,992

Cary D. McMillan

   123,784,882    25,525,822    71,463    10,896,992

Based on the votes set forth above, each of Deborah A. Henretta and Cary D. McMillan were duly elected to serve as Class III directors until the Company’s 2028 Annual Meeting of Stockholders. The following persons continue to serve as Class I directors: Jay L. Schottenstein and Sujatha Chandrasekaran. The following persons continue to serve as Class II directors: Janice E. Page, David M. Sable, and Noel J. Spiegel.

Proposal 2: Votes regarding the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 31, 2026 were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

156,682,017   3,476,545   120,597   -

Based on the votes set forth above, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending January 31, 2026 was duly ratified.

Proposal 3: Votes regarding the approval, on an advisory basis, of the fiscal 2024 compensation of the Company’s named executive officers were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

143,329,390   5,855,515   197,254   10,897,000

Based on the votes set forth above, the fiscal 2024 compensation of the Company’s named executive officers was approved on an advisory, non-binding basis.

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AMERICAN EAGLE OUTFITTERS, INC.
    (Registrant)
Date: July 1, 2025     By:  

/s/ Beth M. Henke

      Beth M. Henke
      Executive Vice President and Chief Legal Officer

FAQ

How many Entrada Therapeutics (TRDA) shares are being registered for sale under this Form 144?

The filing covers 6,422 common shares valued at about USD 45,737.

Who is the seller in the TRDA Form 144 filing?

The shares are being sold for the account of 5AM Opportunities I, L.P., a venture investment fund.

What percentage of Entrada Therapeutics’ outstanding shares does the proposed sale represent?

Approximately 0.02 % of the 37.95 million shares outstanding.

Have there been recent sales by the same shareholder?

Yes. The fund sold 19,265 shares on 27 Jun 2025 and 6,422 shares on 30 Jun 2025, totaling 25,687 shares in three months.

Does the Form 144 filing guarantee that the shares will be sold?

No. Form 144 provides notice of intent; it does not oblige the seller to complete the transaction.
American Eagle Outfitters Inc

NYSE:AEO

AEO Rankings

AEO Latest News

AEO Stock Data

1.68B
161.41M
6.19%
99.06%
8.54%
Apparel Retail
Retail-family Clothing Stores
Link
United States
PITTSBURGH